Putting immunotherapies (like nivolumab) under this category I think will only confuse the reader about the state (and direction) of oncology.
Nivolumab doesn't target cancer cells, it blocks an inhibitory receptor on T-cells, which then kill cancer cells more readily. It's been approved for a wide range of cancer types since it's really a treatment of the immune system:
https://www.drugs.com/history/opdivo.html
Approvals to date: melanoma, lung cancer, kidney cancer, hodgkin lymphoma, head and neck cancer, bladder cancer, MSI-H colorectal cancer.
The distinction between targeted therapies and immunotherapies is very important since, aside from different mechanism, they also tend to have very different trajectories of relapse/resistance. Any metastatic cancer is essentially guaranteed to become resistant to a targeted therapy within 6-18 months. Drugs like nivolumab, on the other hand, offer a minority of patients (10-40% depending on the cancer) a chance at durable responses (cancers either cured or prevented from spreading by immune surveillance).